Table 2 shows the answers of patients regarding general willingness to participate in the preparation process and in the conduction of RCTs (2a) as well as the type of participation (2b)
| Â | n total | Fully agree (1) | partially agree (2) | neutral (3) | partially disagree (4) | fully disagree (5) | No answer |
|---|---|---|---|---|---|---|---|
a – general willingness to participate | |||||||
Patients should participate in the CDP of a clinical trial | 30 | 67% | 17% | 17% | 0% | 0% | 0% |
Patients should participate in the conduction of a clinical trial | 30 | 57% | 27% | 7% | 10% | 0% | 0% |
The involvement of patients improves the quality of clinical trials | 30 | 50% | 33% | 13% | 3% | 0% | 0% |
I would participate in the CDP/conduction of a clinical trial without financial compensation | 30 | 53% | 20% | 20% | 3% | 0% | 3% |
A time expenditure of 10 h per months would be feasible | 30 | 23% | 7% | 7% | 10% | 50% | 3% |
time expenditure of 2 h per months would be feasible | 30 | 70% | 13% | 10% | 0% | 7% | 0% |
b – type of participation | |||||||
Patients should be involved in definition of study endpoints | 30 | 40% | 17% | 27% | 7% | 3% | 7% |
Patients should be involved in definition of inclusion/exclusion criteria | 30 | 27% | 17% | 13% | 23% | 13% | 7% |
Patients should be involved in definition of study specific procedures/examinations | 30 | 17% | 30% | 40% | 3% | 3% | 7% |
Patients should visit meet regularly with the investigators to obtain updates | 30 | 50% | 37% | 7% | 3% | 0% | 3% |